Published 2 days ago • loading... • Updated 2 days ago

Expert: Approval of Semaglutide Major Advancement for CKD, Cardiovascular Risk Reduction in Type 2 Diabetes

Summary by Pharmacy Times

Semaglutide has been approved for reducing kidney disease progression and cardiovascular risk in patients with type 2 diabetes, marking a significant advancement in CKD management.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All

Left

Center

Right

Pharmacy Times

Expert: Approval of Semaglutide Major Advancement for CKD, Cardiovascular Risk Reduction in Type 2 Diabetes

Semaglutide has been approved for reducing kidney disease progression and cardiovascular risk in patients with type 2 diabetes, marking a significant advancement in CKD management.

2 days ago

Read Full Article

Clinical Trials Arena

Type 2 diabetes confers higher risk of cardiovascular disease than type I diabetes

A report published on 12 February 2025 in the Journal of the Society for Cardiovascular Angiography and Interventions by Dr Andrew Goldsweig and colleagues investigated the risk of cardiovascular disease in patients with type I diabetes (T1DM) compared to patients with type 2 diabetes (T2DM).The post Type 2 diabetes confers higher risk of cardiovascular disease than type I diabetes appeared first on Clinical Trials Arena.

2 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources2

Leaning Left0Leaning Right0Center0Last Updated2 days agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Clinical Trials Arena broke the news in 2 days ago on Thursday, February 20, 2025.

Sources are mostly out of (0)

Expert: Approval of Semaglutide Major Advancement for CKD, Cardiovascular Risk Reduction in Type 2 Diabetes

2 Articles

2 Articles

Expert: Approval of Semaglutide Major Advancement for CKD, Cardiovascular Risk Reduction in Type 2 Diabetes

Expert: Approval of Semaglutide Major Advancement for CKD, Cardiovascular Risk Reduction in Type 2 Diabetes

Type 2 diabetes confers higher risk of cardiovascular disease than type I diabetes

Type 2 diabetes confers higher risk of cardiovascular disease than type I diabetes

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics